All News

hip.THR_.jpg

EULAR 2023 – Day 1 Report

Jack Cush, MD

EULAR 2023 launched today to crowds of attendees.  The opening Plenary session and presidential address by Dr.

Read Article
arthritis.RA_.Xray_.hands_.jpg (keep)

An update on JAK inhibitors and cardiovascular risks

Antoni Chan, MD, PhD

In the last 2 years, there has been more caution and vigilance with the use of JAK inhibitors in the treatment of rheumatoid arthritis due to the risk of CV events, including MACE and VTE. The ORAL surveillance study, a post-approval safety study conducted in RA patients aged ≥50 years with ≥1 CV risk factor, has resulted in increased caution and greater emphasis on assessment of MACE and VTE risks in patients starting JAK inhibitors. 

Read Article
Lungs breathing

ILD in RA and PsA

Aurelie Najm, MD, PhD

Interstitial lung disease (ILD) is a severe extra articular manifestation of RA, with limited treatment strategies and poor prognosis.

Read Article
cush.tkr_.jpg

Colchicine and the Risk of Knee and Hip Replacement

Jack Cush, MD

Treatment of osteoarthritis is a major unmet need, as there are few therapies effective at pain control and no options for disease modification; yet a new trial in Annals of Internal Medicine suggest that chronic low dose colchicine may alter disease progression and lower the risk of of total knee and total hip replacements.

Read Article
RheumNow Podcast square

3-4-5 Rule (5.26.2023)

Jack Cush, MD

Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on RheumNow.com.

Read Article
RheumNow Podcast square

Allergic Drug-Induced Arthritis (5.19.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.

Read Article
Can’t escape ORAL Surveillance RCT talk Lots of real world data on CV risk & JAKi here (with all the selection, measurement bias) First up: multinational JAK-pot study (n=>50k) Even if you mirror the high-risk RCT cohort - not much there for MACE OP0219 #EULAR2023 @RheumNow https://t.co/FfNspdivri
David Liew drdavidliew ( View Tweet)
No new predictors for decline in #SSc lung function in ILD Progression of #scleroderma Lung disease is common - risks male, dcSSc, low FVC, Topo1 ⁦@RheumNow⁩ #EULAR2023, OP0236 ⁦@eular_org⁩ https://t.co/bTxTyLE8dZ
Janet Pope Janetbirdope ( View Tweet)
Risks for #ILD #SSc lung progression. FVC decline >5% is the gold standard but there are other criteria. OP0236 #EULAR2023 @RheumNow @eular_org #scleroderma Some criteria are stricter - larger PFT changes and/or worsening symptoms or fibrosis, so depends on def’n for % def’n https://t.co/TCuX2KY64w
Janet Pope Janetbirdope ( View Tweet)
>= 2 tophi and carotid plaque by ultrasound could independently predict major adverse cardiovascular events in addition to conventional CVD risk factors in #gout, data from a single center cohort of 262 pts with 10 yr follow up #EULAR2023 @rheumnow abst#OP0154

Bella Mehta bella_mehta ( View Tweet)

Malignancy in real world datasets: do we see differences between DMARDs - particularly JAKi, with ORAL Surveillance in mind? RABBIT German data (limited risk window): Point estimates slightly up vs TNFi, esp in high CV risk pts but magnitude not big OP0218 #EULAR2023 @RheumNow https://t.co/Ou7TgWvf3b
David Liew drdavidliew ( View Tweet)
#ClinicalPearl Updated #scleroderma Rx recommendations OP0234 New recommendations included ILD, early dcSSc 20 vs prior 16 guidelines. And they recommend ??! Won’t release yet due to importance of wording which will be finalized soon EULAR2023 @RheumNow @eular_org https://t.co/lES6pqkgeT
Janet Pope Janetbirdope ( View Tweet)
The JAK-pot study did not show any significant differences in MACE and other CV outcomes in RA patients treated with JAKi, slight increase signal in VTE/PE, Romain Aymon, Abst#OP0219 #EULAR2023 @RheumNow https://t.co/oPMnw2QmW3
Dr. Antoni Chan synovialjoints ( View Tweet)
We need to assess CV risk in IA but how? Performances of QRisk3, Framingham & Reynolds scores for prediction of CV event in OA RA PsA AS PSO Bummer: these 3 prediction tools are less accurate in IA but also OA. We need a dedicated tool. @Rheumnow OP0267 #EULAR23 https://t.co/O73cETXXoe
Aurelie Najm AurelieRheumo ( View Tweet)
Early Rx with immunosuppressives doesn’t seem to prevent ILD in #scleroderma ? Chanelling bias as dcSSc get more ILD, esp if active disease but in this side it didn’t make a difference #EULAR2023 @RheumNow OP0239 https://t.co/xt0mtpOpYl
Janet Pope Janetbirdope ( View Tweet)
#EULAR2023 #POS0627 Researchers in Manchester identified several proteins associated with subclinical cardiovascular abnormalities on Cardiac MRI in Scleroderma using proteomics. Need validation. Could be useful for stratification and identify therapeutic targets @RheumNow https://t.co/55eNGhMu5f
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2023 #POS0618 This is cool! Researchers from Switzerland are developing new Quantitative Radiomic Risk Score (from HRCT) to stratify response to Anti-Fibrotic in #ILD. Data presented in pre-clinical study & paralleled molecular effects. Human study is in progress @RheumNow https://t.co/qAsWew4FEO
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Scandinavian RA registry study shows reassuring data on CV risk in RA🫀 Acute Coronary Syndrom incidence rates are similar in RA pts achieving remission & general pop & is similar whether RA pts reach remission using MTX or TNFi. https://t.co/wBDZtaTVba OP0038 #EULAR23 @Rheumnow https://t.co/JLdbYF49xF

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Data from combined big Scandinavian population registries looking at both RA and PsA, ILD development, & MTX exposure Here’s the ILD risk for methotrexate. Can we stop this MTX misinformation? No more besmirching a really useful drug for our patients #EULAR2023 OP0006 @RheumNow https://t.co/7swqAYchDC
David Liew drdavidliew ( View Tweet)
New benefit/risk outlook 👀 on ORAL surveillance 2 subgrps: 🟢RA w/ no previous Hx of atherosclerotic CV dis = TOFA at least as good as TNFi AND risk of MACE is comparable 🛑RA w/ HxASCVD = efficacy TOFA = TNFi AND > risk of MACE https://t.co/VOxNQSoyY4 OP0043 #EULAR23 @Rheumnow https://t.co/m98eSMG03U

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×